Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifampin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifampin SCHEMBL14922822 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14029509 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL13230041 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14405975 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14927261 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL19457678 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL23490 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22517710 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22432205 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL66289 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2259799-B1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2014-03-12 | — | — | EP | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| US-7935705-B2 | N-alkylated rifampin | MEDTRONIC, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110028385-A1 | Combination of Immunomodulator and Anti-Pathogenic Agent | NUNES ISEU DA SILVA | 2011-02-03 | — | — | US | disclosed |
| US-20100316681-A1 | N-ALKYLATED RIFAMPIN | MEDTRONIC, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2259799-A1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | Nunes, Iseu Da Silva (BR) | 2010-12-15 | — | — | EP | disclosed |
| US-7799793-B2 | N-alkylated rifampin | MEDTRONIC, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| WO-2009097670-A1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2009-08-13 | — | — | WO | disclosed |
| US-20080268010-A1 | N-ALKYLATED RIFAMPIN | MEDTRONIC, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316681-A1 | N-ALKYLATED RIFAMPIN | FNTB, RIF1, NAT1 | MAPT 2322/4885NR1I2 228/4885ABCB11 8/4885 |
| US-20080268010-A1 | N-ALKYLATED RIFAMPIN | FNTB, RIF1, NAT1 | MAPT 2322/4885NR1I2 228/4885ABCB11 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.